Complete morphologic and molecular remission after introduction of dasatinib in the treatment of a pediatric patient with t-cell acute lymphoblastic leukemia and ABL1 amplification
T‐cell acute lymphoblastic leukemia (ALL) accounts for 15% of ALL cases in children and has been associated with a worse prognosis. Cytogenetic studies show an abnormal karyotype in 50–60% of the T‐cell ALL patients; ABL1 fusions are present in approximately 8% of the cases. Dasatinib, a second‐gene...
Gespeichert in:
| Veröffentlicht in: | Pediatric blood & cancer 2012-08, Vol.59 (2), p.333-334 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 334 |
|---|---|
| container_issue | 2 |
| container_start_page | 333 |
| container_title | Pediatric blood & cancer |
| container_volume | 59 |
| creator | Crombet, Ofelia Lastrapes, Kelly Zieske, Arthur Morales-Arias, Jaime |
| description | T‐cell acute lymphoblastic leukemia (ALL) accounts for 15% of ALL cases in children and has been associated with a worse prognosis. Cytogenetic studies show an abnormal karyotype in 50–60% of the T‐cell ALL patients; ABL1 fusions are present in approximately 8% of the cases. Dasatinib, a second‐generation tyrosine kinase inhibitor, directly targets the BCR‐ABL gene. We describe a pediatric case of T‐cell ALL with amplification of the ABL1 gene in which remission was achieved only after the addition of dasatinib to conventional chemotherapy. Pediatr Blood Cancer 2012;59:333–334. © 2011 Wiley Periodicals, Inc. |
| doi_str_mv | 10.1002/pbc.23327 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1020189756</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1020189756</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3637-fafc53db28fcea9784c42ce37cae8518ee41fa2673fe3d8c71b21b76be0f96393</originalsourceid><addsrcrecordid>eNp1kc1u1DAUhSMEoqWw4AWQl7BIG9uTOFl2AhSkASrx06V141wzpk4cbEftvFcfEKfTzo6V7Xs_n3Ptk2WvaXFKi4KdTZ06ZZwz8SQ7puWqzMuCiqeHfdEcZS9C-JPQqijr59kRY1XdMEqPs7vWDZPFiGRwfto6634bRWDs09mimi144nEwIRg3EtARPTFj9K6fVVxKTpMeAkQzmi51SNwiiR4hDjjGpQtkwt5A9El3StxSvjFxS2Ku0FoCak7udjck985CiImzOF8nU7gf5Hy9oQTSlEYbBYvpy-yZBhvw1cN6kv38-OFH-ynffLv43J5vcsUrLnINWpW871itFUIj6pVaMYVcKMC6pDXiimpgleAaeV8rQTtGO1F1WOim4g0_yd7udSfv_s4YokwfsQwNI7o5SFqwgtaNKKuEvtujyrsQPGo5eTOA3yVILiHJFJK8Dymxbx5k527A_kA-ppKAsz1wYyzu_q8kL9fto2S-v2FCxNvDDfDXMj1PlPLq64X88r39dfl-TeUV_we9hK_A</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1020189756</pqid></control><display><type>article</type><title>Complete morphologic and molecular remission after introduction of dasatinib in the treatment of a pediatric patient with t-cell acute lymphoblastic leukemia and ABL1 amplification</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Crombet, Ofelia ; Lastrapes, Kelly ; Zieske, Arthur ; Morales-Arias, Jaime</creator><creatorcontrib>Crombet, Ofelia ; Lastrapes, Kelly ; Zieske, Arthur ; Morales-Arias, Jaime</creatorcontrib><description>T‐cell acute lymphoblastic leukemia (ALL) accounts for 15% of ALL cases in children and has been associated with a worse prognosis. Cytogenetic studies show an abnormal karyotype in 50–60% of the T‐cell ALL patients; ABL1 fusions are present in approximately 8% of the cases. Dasatinib, a second‐generation tyrosine kinase inhibitor, directly targets the BCR‐ABL gene. We describe a pediatric case of T‐cell ALL with amplification of the ABL1 gene in which remission was achieved only after the addition of dasatinib to conventional chemotherapy. Pediatr Blood Cancer 2012;59:333–334. © 2011 Wiley Periodicals, Inc.</description><identifier>ISSN: 1545-5009</identifier><identifier>EISSN: 1545-5017</identifier><identifier>DOI: 10.1002/pbc.23327</identifier><identifier>PMID: 22689211</identifier><language>eng</language><publisher>Hoboken: Wiley Subscription Services, Inc., A Wiley Company</publisher><subject>ABL1 amplification ; acute lymphoblastic leukemia ; Child ; Dasatinib ; Female ; Gene Amplification ; Humans ; leukemia treatment ; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma - drug therapy ; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma - genetics ; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma - pathology ; Protein Kinase Inhibitors - therapeutic use ; Proto-Oncogene Proteins c-abl - genetics ; Pyrimidines - therapeutic use ; Remission Induction ; T-cell ALL ; Thiazoles - therapeutic use</subject><ispartof>Pediatric blood & cancer, 2012-08, Vol.59 (2), p.333-334</ispartof><rights>Copyright © 2011 Wiley Periodicals, Inc.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3637-fafc53db28fcea9784c42ce37cae8518ee41fa2673fe3d8c71b21b76be0f96393</citedby><cites>FETCH-LOGICAL-c3637-fafc53db28fcea9784c42ce37cae8518ee41fa2673fe3d8c71b21b76be0f96393</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fpbc.23327$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fpbc.23327$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,27903,27904,45553,45554</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/22689211$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Crombet, Ofelia</creatorcontrib><creatorcontrib>Lastrapes, Kelly</creatorcontrib><creatorcontrib>Zieske, Arthur</creatorcontrib><creatorcontrib>Morales-Arias, Jaime</creatorcontrib><title>Complete morphologic and molecular remission after introduction of dasatinib in the treatment of a pediatric patient with t-cell acute lymphoblastic leukemia and ABL1 amplification</title><title>Pediatric blood & cancer</title><addtitle>Pediatr. Blood Cancer</addtitle><description>T‐cell acute lymphoblastic leukemia (ALL) accounts for 15% of ALL cases in children and has been associated with a worse prognosis. Cytogenetic studies show an abnormal karyotype in 50–60% of the T‐cell ALL patients; ABL1 fusions are present in approximately 8% of the cases. Dasatinib, a second‐generation tyrosine kinase inhibitor, directly targets the BCR‐ABL gene. We describe a pediatric case of T‐cell ALL with amplification of the ABL1 gene in which remission was achieved only after the addition of dasatinib to conventional chemotherapy. Pediatr Blood Cancer 2012;59:333–334. © 2011 Wiley Periodicals, Inc.</description><subject>ABL1 amplification</subject><subject>acute lymphoblastic leukemia</subject><subject>Child</subject><subject>Dasatinib</subject><subject>Female</subject><subject>Gene Amplification</subject><subject>Humans</subject><subject>leukemia treatment</subject><subject>Precursor T-Cell Lymphoblastic Leukemia-Lymphoma - drug therapy</subject><subject>Precursor T-Cell Lymphoblastic Leukemia-Lymphoma - genetics</subject><subject>Precursor T-Cell Lymphoblastic Leukemia-Lymphoma - pathology</subject><subject>Protein Kinase Inhibitors - therapeutic use</subject><subject>Proto-Oncogene Proteins c-abl - genetics</subject><subject>Pyrimidines - therapeutic use</subject><subject>Remission Induction</subject><subject>T-cell ALL</subject><subject>Thiazoles - therapeutic use</subject><issn>1545-5009</issn><issn>1545-5017</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kc1u1DAUhSMEoqWw4AWQl7BIG9uTOFl2AhSkASrx06V141wzpk4cbEftvFcfEKfTzo6V7Xs_n3Ptk2WvaXFKi4KdTZ06ZZwz8SQ7puWqzMuCiqeHfdEcZS9C-JPQqijr59kRY1XdMEqPs7vWDZPFiGRwfto6634bRWDs09mimi144nEwIRg3EtARPTFj9K6fVVxKTpMeAkQzmi51SNwiiR4hDjjGpQtkwt5A9El3StxSvjFxS2Ku0FoCak7udjck985CiImzOF8nU7gf5Hy9oQTSlEYbBYvpy-yZBhvw1cN6kv38-OFH-ynffLv43J5vcsUrLnINWpW871itFUIj6pVaMYVcKMC6pDXiimpgleAaeV8rQTtGO1F1WOim4g0_yd7udSfv_s4YokwfsQwNI7o5SFqwgtaNKKuEvtujyrsQPGo5eTOA3yVILiHJFJK8Dymxbx5k527A_kA-ppKAsz1wYyzu_q8kL9fto2S-v2FCxNvDDfDXMj1PlPLq64X88r39dfl-TeUV_we9hK_A</recordid><startdate>201208</startdate><enddate>201208</enddate><creator>Crombet, Ofelia</creator><creator>Lastrapes, Kelly</creator><creator>Zieske, Arthur</creator><creator>Morales-Arias, Jaime</creator><general>Wiley Subscription Services, Inc., A Wiley Company</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>201208</creationdate><title>Complete morphologic and molecular remission after introduction of dasatinib in the treatment of a pediatric patient with t-cell acute lymphoblastic leukemia and ABL1 amplification</title><author>Crombet, Ofelia ; Lastrapes, Kelly ; Zieske, Arthur ; Morales-Arias, Jaime</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3637-fafc53db28fcea9784c42ce37cae8518ee41fa2673fe3d8c71b21b76be0f96393</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>ABL1 amplification</topic><topic>acute lymphoblastic leukemia</topic><topic>Child</topic><topic>Dasatinib</topic><topic>Female</topic><topic>Gene Amplification</topic><topic>Humans</topic><topic>leukemia treatment</topic><topic>Precursor T-Cell Lymphoblastic Leukemia-Lymphoma - drug therapy</topic><topic>Precursor T-Cell Lymphoblastic Leukemia-Lymphoma - genetics</topic><topic>Precursor T-Cell Lymphoblastic Leukemia-Lymphoma - pathology</topic><topic>Protein Kinase Inhibitors - therapeutic use</topic><topic>Proto-Oncogene Proteins c-abl - genetics</topic><topic>Pyrimidines - therapeutic use</topic><topic>Remission Induction</topic><topic>T-cell ALL</topic><topic>Thiazoles - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Crombet, Ofelia</creatorcontrib><creatorcontrib>Lastrapes, Kelly</creatorcontrib><creatorcontrib>Zieske, Arthur</creatorcontrib><creatorcontrib>Morales-Arias, Jaime</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Pediatric blood & cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Crombet, Ofelia</au><au>Lastrapes, Kelly</au><au>Zieske, Arthur</au><au>Morales-Arias, Jaime</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Complete morphologic and molecular remission after introduction of dasatinib in the treatment of a pediatric patient with t-cell acute lymphoblastic leukemia and ABL1 amplification</atitle><jtitle>Pediatric blood & cancer</jtitle><addtitle>Pediatr. Blood Cancer</addtitle><date>2012-08</date><risdate>2012</risdate><volume>59</volume><issue>2</issue><spage>333</spage><epage>334</epage><pages>333-334</pages><issn>1545-5009</issn><eissn>1545-5017</eissn><abstract>T‐cell acute lymphoblastic leukemia (ALL) accounts for 15% of ALL cases in children and has been associated with a worse prognosis. Cytogenetic studies show an abnormal karyotype in 50–60% of the T‐cell ALL patients; ABL1 fusions are present in approximately 8% of the cases. Dasatinib, a second‐generation tyrosine kinase inhibitor, directly targets the BCR‐ABL gene. We describe a pediatric case of T‐cell ALL with amplification of the ABL1 gene in which remission was achieved only after the addition of dasatinib to conventional chemotherapy. Pediatr Blood Cancer 2012;59:333–334. © 2011 Wiley Periodicals, Inc.</abstract><cop>Hoboken</cop><pub>Wiley Subscription Services, Inc., A Wiley Company</pub><pmid>22689211</pmid><doi>10.1002/pbc.23327</doi><tpages>2</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1545-5009 |
| ispartof | Pediatric blood & cancer, 2012-08, Vol.59 (2), p.333-334 |
| issn | 1545-5009 1545-5017 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1020189756 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete |
| subjects | ABL1 amplification acute lymphoblastic leukemia Child Dasatinib Female Gene Amplification Humans leukemia treatment Precursor T-Cell Lymphoblastic Leukemia-Lymphoma - drug therapy Precursor T-Cell Lymphoblastic Leukemia-Lymphoma - genetics Precursor T-Cell Lymphoblastic Leukemia-Lymphoma - pathology Protein Kinase Inhibitors - therapeutic use Proto-Oncogene Proteins c-abl - genetics Pyrimidines - therapeutic use Remission Induction T-cell ALL Thiazoles - therapeutic use |
| title | Complete morphologic and molecular remission after introduction of dasatinib in the treatment of a pediatric patient with t-cell acute lymphoblastic leukemia and ABL1 amplification |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-27T19%3A01%3A16IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Complete%20morphologic%20and%20molecular%20remission%20after%20introduction%20of%20dasatinib%20in%20the%20treatment%20of%20a%20pediatric%20patient%20with%20t-cell%20acute%20lymphoblastic%20leukemia%20and%20ABL1%20amplification&rft.jtitle=Pediatric%20blood%20&%20cancer&rft.au=Crombet,%20Ofelia&rft.date=2012-08&rft.volume=59&rft.issue=2&rft.spage=333&rft.epage=334&rft.pages=333-334&rft.issn=1545-5009&rft.eissn=1545-5017&rft_id=info:doi/10.1002/pbc.23327&rft_dat=%3Cproquest_cross%3E1020189756%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1020189756&rft_id=info:pmid/22689211&rfr_iscdi=true |